Skip to main content

Table 2 Baseline characteristics of 193 ever-smokers with locoregionally advanced nasopharyngeal carcinoma

From: The impact of smoking on the clinical outcome of locoregionally advanced nasopharyngeal carcinoma after chemoradiotherapy

 

Light, short-term

Light, long-term

Heavy, short-term

Heavy, long-term

P value

 

32(16.8%)

18(8.4%)

57(29.8%)

86(45.0%)

 

Age, yr, median

40(20-58)

50(36-60)

39(24-59)

49(10-66)

0.452

Gender

    

0.005

Female

1(3.1)

1(12.5)

0

0

 

Male

31(96.9)

17(87.5)

57(100)

86(100)

 

T stage

    

0.368

1-2

7(21.9)

1(5.6)

8(14.0)

13(15.1)

 

3-4

25(78.1)

17(94.4)

49(86.0)

73(84.9)

 

N stage

    

0.463

0-1

16(48.5)

6(33.3)

25(43.9)

45(52.3)

 

2-3

17(51.5)

12(66.7)

32(56.1)

41(47.7)

 

Clinical stage

    

0.189

3

15(46.9)

14(75.0)

34(59.6)

43(50.0)

 

4

17(53.1)

4(25.0)

23(40.4)

43(50.0)

 

Treatment arm

    

0.641

IC + CCRT

16(50.0)

11(61.1)

32(56.1)

41(47.7)

 

IC + RT

16(50.0)

7(38.9)

25(43.9)

45(52.3)

 

RT dose(Gy),median(range)

72(68-78)

72(68-78)

72(68-78)

72(68-78)

0.118

CT course, median(range)

2(2-5)

32(1-5)

22(1-5)

22(1-5)

0.470

RT interruption

     

Yes

2(6.2)

0(0)

1(1.8)

1(1.2)

0.337

No

30(93.8)

18(100)

55(98.2)

85(98.8)

 

AMT

    

0.731

1-2

30(93.8)

18(100)

52(92.9)

80(93.0)

 

3-4

2(6.2)

0(0)

4(7.1)

6(7.0)

 

VCA-IgA

    

0.330

Positive(≥1:80)

30(93.8)

17(94.4)

47(83.9)

79(91.9)

 

Negative

2(6.3)

1(5.6)

9(16.1)

7(8.1)

 

EA-IgA

    

0.121

Positive(≥1:10)

27(84.4)

17(94.4)

39(69.6)

67(77.9)

 

Negative

5(15.6)

1(5.6)

17(30.4)

19(22.1)

 

Median follow-up yr (range)

6.8(0.5-8.7)

6.9(1.1-8.3)

6.5(0.2-8.6)

6.2(0.6-9.0)

0.572

  1. Abbreviations: IC + CCRT = induction chemotherapy plus concurrent chemoradiotherapy and IC + RT = induction chemotherapy plus radiotherapy. AMT = Acute mucosal toxicity.